Drug Trial Radar · NCT07513376
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
876
Planned (sponsor's estimate)
Start
May 4, 2026
Primary completion
Aug 22, 2034
Study completion May 11, 2038
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- Collaborators
- ModernaTX, Inc.
- First posted
- Apr 7, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for new ways to treat high-risk, localized non-small cell lung cancer (NSCLC) that has been removed with surgery. People with high-risk, localized NSCLC are often treated with surgery. Researchers want to learn if participants can receive 1 or 2 trial treatments to help prevent NSCLC from coming back after surgery. One trial medicine is intismeran (also called V940/mRNA-4157) and the other is subcutaneous pembrolizumab (also called SC pembrolizumab and MK-3475A). Intismeran is designed to help a person's immune system attack their specific cancer. SC pembrolizumab is an immunotherapy treatment which helps the immune system fight cancer. The main purpose of this study is to evaluate whether adjuvant intismeran autogene (V940) in combination with SC pembrolizumab and berahyaluronidase alfa (MK-3475A) or intismeran monotherapy improves disease-free survival (DFS) compared with placebo in participants with completely resected high-risk Stage I NSCLC.
Conditions
- Non-small Cell Lung Cancer
Interventions
IntismeranBiological
IM injection
Pembrolizumab coformulated with berahyaluronidase alfaBiological
SC injection
PlaceboOther
IM injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease-Free Survival (DFS) as Assessed by Blinded Independent Central Review (BICR) in Participants With Nonsquamous Non-Small Cell Lung Cancer (NSCLC) in Arm A and Arm CTime frame: Up to approximately 98 months
Locations
129 sites in 20 countries. Site status is shown where the registry gives one.
UC Davis Comprehensive Cancer Center ( Site 3204)
Sacramento, California · Recruiting
University of Colorado Cancer Center ( Site 3268)
Aurora, Colorado · Recruiting
Smilow Cancer Center at Yale-New Haven ( Site 3253)
New Haven, Connecticut · Recruiting
UF Health Cancer Center ( Site 3257)
Gainesville, Florida · Recruiting
Illinois Cancer Care ( Site 7000)
Peoria, Illinois · Recruiting
Trinity Health Saint Joseph Mercy Hospital Ann Arbor ( Site 9509)
Ypsilanti, Michigan · Recruiting
Washington University School of Medicine ( Site 3279)
St Louis, Missouri · Recruiting
Billings Clinic ( Site 3255)
Billings, Montana · Recruiting
NHO Revive Research Institute, LLC ( Site 3218)
Lincoln, Nebraska · Recruiting
Renown Regional Medical Center-Renown Health Medical Oncology ( Site 3207)
Reno, Nevada · Recruiting
New York Oncology Hematology, P.C. ( Site 9000)
Albany, New York · Recruiting
Memorial Sloan Kettering Cancer Center ( Site 3296)
New York, New York · Recruiting
SUNY Upstate Medical University ( Site 3270)
Syracuse, New York · Recruiting
White Plains Hospital ( Site 3213)
White Plains, New York · Recruiting
Charles George VA Medical Center ( Site 3233)
Asheville, North Carolina · Recruiting
UNC Lineberger Comprehensive Cancer Center ( Site 3250)
Chapel Hill, North Carolina · Recruiting
WakeMed Raleigh Campus ( Site 3214)
Raleigh, North Carolina · Recruiting
Sanford Fargo Medical Center ( Site 3236)
Fargo, North Dakota · Recruiting
Altru Health System ( Site 3254)
Grand Forks, North Dakota · Recruiting
Perelman Center for Advanced Medicine ( Site 3205)
Philadelphia, Pennsylvania · Recruiting
Sanford Cancer Center ( Site 3266)
Sioux Falls, South Dakota · Recruiting
Avera Cancer Institute ( Site 3209)
Sioux Falls, South Dakota · Recruiting
The University of Tennessee Medical Center ( Site 3223)
Knoxville, Tennessee · Recruiting
University of Texas-MD Anderson Cancer Center ( Site 3283)
Houston, Texas · Recruiting
Hematology Oncology Associates of Fredericksburg ( Site 3275)
Fredericksburg, Virginia · Recruiting
Fred Hutchinson Cancer Center ( Site 3202)
Seattle, Washington · Recruiting
West Virginia University ( Site 3237)
Morgantown, West Virginia · Recruiting
Gundersen Health System ( Site 3200)
La Crosse, Wisconsin · Recruiting
Royal North Shore Hospital ( Site 0502)
St Leonards, New South Wales, Australia · Recruiting
Princess Alexandra Hospital ( Site 0503)
Brisbane, Queensland, Australia · Recruiting
One Clinical Research ( Site 0501)
Nedlands, Western Australia, Australia · Recruiting
Hospital Samaritano De Sao Paulo ( Site 3612)
São Paulo, Brazil · Recruiting
Hospital Sírio Libanês ( Site 3611)
São Paulo, Brazil · Recruiting
Hospital de Clínicas de Passo Fundo ( Site 3601)
Pasos Fundo, Rio Grande do Sul, Brazil · Recruiting
Hamilton Health Sciences-Juravinski Cancer Centre ( Site 2506)
Hamilton, Ontario, Canada · Recruiting
Kingston Health Sciences Centre-Kingston General Hospital Site ( Site 2503)
Kingston, Ontario, Canada · Recruiting
The Ottawa Hospital Cancer Centre ( Site 2508)
Ottawa, Ontario, Canada · Recruiting
Centre Hospitalier de l'Université de Montréal ( Site 2501)
Montreal, Quebec, Canada · Recruiting
Bradford Hill Norte ( Site 3705)
Antofagasta, Chile · Recruiting
Clínica MEDS La Dehesa ( Site 3708)
Lo Barnechea, Region M. de Santiago, Chile · Recruiting
Showing 40 of 129 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.